News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
197 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17924)
Month
January (4450)
February (4428)
March (5683)
April (4545)
May (5703)
June (4805)
July (3912)
August (4762)
September (4260)
October (3860)
November (4837)
December (2683)
Day
2 (18)
3 (192)
4 (399)
5 (344)
6 (307)
7 (143)
8 (3)
9 (40)
10 (389)
11 (192)
12 (199)
13 (188)
14 (96)
15 (3)
16 (29)
17 (74)
18 (340)
19 (185)
20 (212)
21 (85)
22 (1)
23 (15)
24 (197)
25 (192)
26 (163)
27 (186)
28 (90)
29 (1)
30 (4)
31 (163)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Biotech Bay
Agilent Announces the Innovative Seahorse XF Pro Analyzer
Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools.
January 24, 2022
·
3 min read
Relief Therapeutics’ Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, has received a Notice of Allowance from the U.S. Patent and Trademark Office for Patent Application No. 16/713,052 entitled, “Ready to Use Diclofenac Packs.”.
January 24, 2022
·
4 min read
GenSight Biologics Reports Clinically Meaningful Vision Improvement is Maintained 4 Years After One-time Treatment with LUMEVOQ® Gene Therapy
GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported that Leber Hereditary Optical Neuropathy subjects treated with LUMEVOQ® continued to experience significantly improved vision four years after a single injection of the gene therapy.
January 24, 2022
·
12 min read
Biotech Bay
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma
Innovent Biologics, Inc. announced that the Hong Kong Department of Health (DH) has approved Pemazyre®.
January 24, 2022
·
9 min read
XPhyto Provides Update on Integration of 3a-diagnostics GmbH
XPhyto Therapeutics Corp. is pleased to provide an update on the integration of 3a-diagnostics GmbH into XPhyto’s German operations.
January 24, 2022
·
5 min read
Genetown
ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI
ERYTECH Pharma announced presentation of results of two trials evaluating eryaspasein advanced pancreatic cancerat the American Society of Clinical Oncology Gastrointestinal Cancers Symposium on January 21, 2022.
January 24, 2022
·
10 min read
Drug Development
Harbour BioMed Announces Dosing of First Patient in Combination Therapy Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody
Harbour BioMed announced that, it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of dose expansion of its anti-CTLA-4 antibody in combination therapy with toripalimab for patients suffering from advanced melanoma and other solid tumors.
January 24, 2022
·
2 min read
Previous
20 of 20